Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor-κB and Simian Virus 40 Promoter Factor 1 Pathways

Jörg H. W. Distler, Claudia Hagen, Astrid Hirth, Ulf Müller-Ladner, Hanns M. Lorenz, Angela del Rosso, Beat A. Michel, Renate E. Gay, Ratanavadee Nanagara, Kusuki Nishioka, Marco Matucci-Cerinic, Joachim R. Kalden, Steffen Gay and Oliver Distler
Molecular Pharmacology February 2004, 65 (2) 389-399; DOI: https://doi.org/10.1124/mol.65.2.389
Jörg H. W. Distler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Hagen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Astrid Hirth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulf Müller-Ladner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanns M. Lorenz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela del Rosso
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beat A. Michel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renate E. Gay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ratanavadee Nanagara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kusuki Nishioka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Matucci-Cerinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim R. Kalden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steffen Gay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Distler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The pathogenesis of systemic sclerosis (SSc) is characterized by activation of the immune system, impaired angiogenesis, and activated dermal fibroblasts. The effects of the immunosuppressive agent bucillamine (SA 96) on fibroblasts and angiogenic factors have not been examined. SA 96, and particularly its metabolite SA 981, increased the levels of vascular endothelial growth factor (VEGF) mRNA and protein dose-dependently in dermal fibroblasts from patients with SSc and healthy control subjects without influencing cell viability. SSc fibroblast cultures showed consistently a higher inducibility of VEGF than cultures from healthy control subjects. Preincubation with the SP-1 inhibitor mithramycin as well as blockade of nuclear factor (NF)-κB signaling with pyrrolidine dithiocarbamate treatment and IκB transfection reduced significantly the transcription of VEGF, indicating that both transcription factors contribute to the activation of VEGF by SA 981. Specific binding of NF-κB protein to its binding site after treatment with SA 981 was confirmed by electrophoretic mobility shift assay. In contrast, SA 981 did not influence the stability of VEGF mRNA as analyzed with actinomycin D assays. The study provides evidence for a role of NF-κB in the transcriptional regulation of the VEGF gene. SA 96 might have positive aspects on the impaired angiogenesis in patients with SSc.

  • Received July 10, 2003.
  • Accepted October 30, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 65 (2)
Molecular Pharmacology
Vol. 65, Issue 2
1 Feb 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor-κB and Simian Virus 40 Promoter Factor 1 Pathways
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor-κB and Simian Virus 40 Promoter Factor 1 Pathways

Jörg H. W. Distler, Claudia Hagen, Astrid Hirth, Ulf Müller-Ladner, Hanns M. Lorenz, Angela del Rosso, Beat A. Michel, Renate E. Gay, Ratanavadee Nanagara, Kusuki Nishioka, Marco Matucci-Cerinic, Joachim R. Kalden, Steffen Gay and Oliver Distler
Molecular Pharmacology February 1, 2004, 65 (2) 389-399; DOI: https://doi.org/10.1124/mol.65.2.389

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor-κB and Simian Virus 40 Promoter Factor 1 Pathways

Jörg H. W. Distler, Claudia Hagen, Astrid Hirth, Ulf Müller-Ladner, Hanns M. Lorenz, Angela del Rosso, Beat A. Michel, Renate E. Gay, Ratanavadee Nanagara, Kusuki Nishioka, Marco Matucci-Cerinic, Joachim R. Kalden, Steffen Gay and Oliver Distler
Molecular Pharmacology February 1, 2004, 65 (2) 389-399; DOI: https://doi.org/10.1124/mol.65.2.389
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Anti-aromatase activity of exemestane phase II metabolites
  • α-Conotoxin Binding Site on the GABAB Receptor
  • Upacicalcet binds to the amino acid binding site of CaSR
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics